Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | RAD52 | P43351 | 1/20 | 0.64 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TERT | O14746 | 13/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | PTPRC | P08575 | 1/20 | 0.58 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8707594 | 0.95 | TERT (0.68) | MEN1ALDH1A1POLBGAAMAPT | |
| SCHEMBL1304418 | 0.94 | TERT (0.69) | MEN1ALDH1A1POLBGAAMAPT | |
| SCHEMBL8707320 | 0.92 | MEN1 (0.62) | MEN1ALDH1A1POLBGAAMAPT | |
| SCHEMBL14240480 | 0.90 | TERT (0.66) | MEN1ALDH1A1POLBGAAMAPT | |
| SCHEMBL30237734 | 0.89 | TERT (0.65) | MEN1ALDH1A1POLBGAAMAPT | |
| SCHEMBL6367460 | 0.89 | TERT (0.65) | MEN1ALDH1A1POLBGAAMAPT | |
| SCHEMBL12111899 | 0.89 | TERT (0.67) | MEN1ALDH1A1POLBGAAMAPT | |
| SCHEMBL3381039 | 0.88 | MAOA (0.65) | MEN1ALDH1A1POLBGAAMAPT | |
| SCHEMBL12111904 | 0.87 | TERT (0.61) | MEN1ALDH1A1POLBGAAMAPT | |
| SCHEMBL5804635 | 0.85 | MEN1 (0.68) | MEN1ALDH1A1POLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316234-A1 | ANTHRAQUINONE -BASED COMPOUND, THE SYNTHESIS PROCESSES AND THE APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-12-13 | — | — | US | disclosed |
| WO-1998025884-A1 | FURTHER ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998025885-A1 | ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316234-A1 | ANTHRAQUINONE -BASED COMPOUND, THE SYNTHESIS PROCESSES AND THE APPLICATION THEREOF | AAAS, QPCT, NQO2 | MEN1 2110/4885ALDH1A1 1002/4885POLB 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.